$2.83
3.86% today
Nasdaq, Apr 02, 09:15 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Stock price

$2.72
-0.36 11.69% 1M
-0.25 8.42% 6M
-0.69 20.23% YTD
-0.26 8.72% 1Y
-16.44 85.80% 3Y
-53.18 95.13% 5Y
-53.18 95.13% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.05 1.81%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $610.11m
Enterprise Value $40.10m
P/E (TTM) P/E ratio 4.95
EV/FCF (TTM) EV/FCF 0.35
EV/Sales (TTM) EV/Sales 0.07
P/S ratio (TTM) P/S ratio 1.02
P/B ratio (TTM) P/B ratio 0.75
Revenue growth (TTM) Revenue growth 1,202.27%
Revenue (TTM) Revenue $595.81m
EBIT (operating result TTM) EBIT $179.96m
Free Cash Flow (TTM) Free Cash Flow $113.23m
Cash position $614.79m
EPS (TTM) EPS $0.55
P/E forward 3.17
P/S forward 1.09
EV/Sales forward 0.07
Short interest 10.12%
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CureVac N.V. forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
596 596
1,202% 1,202%
100%
- Direct Costs 192 192
8% 8%
32%
404 404
406% 406%
68%
- Selling and Administrative Expenses 52 52
20% 20%
9%
- Research and Development Expense 145 145
32% 32%
24%
206 206
167% 167%
35%
- Depreciation and Amortization 26 26
15% 15%
4%
EBIT (Operating Income) EBIT 180 180
154% 154%
30%
Net Profit 124 124
139% 139%
21%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Positive
Market Watch
5 days ago
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
Positive
Reuters
6 days ago
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
Neutral
Accesswire
6 days ago
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, rec...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today